Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 3, 2013, Pages 2763-2769

  Gill, Kamaldeep ^a   Singh, Abhay K ^a   Kapoor, Vaishali ^a   Nigam, Lokesh ^b   Kumar, Rahul ^a   Holla, Prasida ^a   Das, Satya N ^a   Yadav, Savita ^a   Subbarao, Naidu ^b   Mohanti, Bidhu K ^a   Dey, Sharmistha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Anticancer; Apoptosis; HNSCC; p38 ; Tetrapeptide

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; CASPASE 7; MITOGEN ACTIVATED PROTEIN KINASE 14; PHENYLALANYLTRYPTOPHANYLTYROSYLSERINE; TETRAPEPTIDE; TRYPTOPHANYLPHENYLALANYLVALYLGLUTAMATE; TYROSYLTRYPTOPHANYLCYSTEINYLSERINE; UNCLASSIFIED DRUG; VALYLPHENYLALANYLLYSYLSERINE; VALYLTRYPTOPHANYLCYSTEINYLSERINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMOLYSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR MODEL; MOUTH CANCER; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; OLIGOPEPTIDES; PROTEIN BINDING; RECOMBINANT PROTEINS;

EID: 84873596282     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.12.001     Document Type: Article

References (23)

1. P.C. Gupta, and A. Nandakumar Oral cancer scene in India Oral Dis. 5 1999 1 2
2. B.W. Neville, and T.A. Day Oral cancer and precancerous lesions CA Cancer J. Clin. 52 2002 195 215
3. S.L. Pelech, and J.S. Sanghera MAP kinases: charting the regulatory pathways Science 257 1992 1355 1356
4. G. Pedraza-Alva, M. Koulnis, C. Charland, T. Thornton, J.L. Clements, M.S. Schlissel, and M. Rincon Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint EMBO J. 25 2006 763 773
5. A.K. Greenberg, S. Basu, J. Hu, T.A. Yie, K.M. Tchou-Wong, W.N. Rom, and T.C. Lee Selective p38 activation in human non-small cell lung cancer Am. J. Respir. Cell Mol. Biol. 26 2002 558 564
6. K. Gill, B.K. Mohanti, M.S. Ashraf, A.K. Singh, and S. Dey Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy Clin. Chim. Acta 413 2012 219 225
7. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
8. M. Boussac, and J. Garin Calcium-dependent secretion in human neutrophils: a proteomic approach Electrophoresis 21 2000 665 672
9. M. Kinter, and N.E. Sherman Protein Sequencing and Identification Using Tandem Mass Spectrometry Wiley Intersciences series 2000
10. P. Forrer, R. Tamaskovic, and R. Jaussi Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities Biol. Chem. 379 1998 1101 1111
11. W.H. Lee, R. Bookstein, F. Hong, L.J. Young, J.Y. Shew, and E.Y. Lee Human retinoblastoma susceptibility gene: cloning, identification and sequence Science 235 1987 1394 1399
12. W.L. De Lano The PyMOL Molecular Graphics System, Version 1.2r3pre 2002 Schrödinger, LLC http://www.pymol.org
13. R.B. Merrifield Solid phase peptide synthesis. The synthesis of a tetrapeptide J. Am. Chem. Soc. 85 1963 2149 2154
14. D. Casper, M. Bukhtiyarova, and E.B. Springman Comparison of p38 kinase inhibitor binding affinity and kinetics using Biacore Biacore 3 2003 4 7
15. J.C. Boehm, M.J. Bower, T.F. Gallagher, S. Kassis, S.R. Johnson, and J.L. Adams Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles Bioorg. Med. Chem. Lett. 11 2001 1123 1126
16. W.H. Taylor Serum enzymes in the diagnosis of disease Br. J. Anaesth. 41 1969 227 234
17. S.R. Natarajan, S.T. Heller, K. Nam, S.B. Singh, G. Scapin, S. Patel, J.E. Thompson, C.E. Fitzgerald, and S.J. O'Keefe p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design Bioorg. Med. Chem. Lett. 16 2006 5809 5813
18. L. Tong, S. Pav, D.M. White, S. Rogers, K.M. Crane, C.L. Cywin, M.L. Brown, and C.A. Pargellis A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket Nat. Struct. Biol. 4 1997 311 316
19. Z. Wang, B.J. Canagarajah, J.C. Boehm, S. Kassisa, M.H. Cobb, P.R. Young, S. Abdel-Meguid, J.L. Adams, and E.J. Goldsmith Structural basis of inhibitor selectivity in MAP kinases Structure 6 1998 1117 1128
20. J.C. Lee, S. Kassis, S. Kumar, A. Badger, and J.L. Adams p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials Pharmacol. Ther. 82 1999 389 397
21. K.P. Wilson, P.G. McCaffrey, K. Hsiao, S. Pazhanisamy, V. Galullo, G.W. Bemis, M.J. Fitzgibbon, P.R. Caron, M.A. Murcko, and M.S. Su The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase Chem. Biol. 4 1997 423 431
22. C. Riebe, R. Pries, A. Kemkers, and B. Wollenberg Increased cytokine secretion in head and neck cancer upon p38 mitogen-activated protein kinase activation Int. J. Mol. Med. 20 2007 883 887
23. R. Pries, and B. Wollenberg Cytokines in head and neck cancer Cytokine Growth Factor Rev. 17 2006 141 146